Immutep (IMMP) announces that patient enrolment has been completed in the investigator-initiated EFTISARC-NEO trial. EFTISARC-NEO is evaluating eftilagimod alpha in combination with radiotherapy plus KEYTRUDA in the neoadjuvant setting for patients with resectable soft tissue sarcoma, STS. The Phase II trial conducted by the Maria Skodowska-Curie National Research Institute of Oncology in Warsaw, the national reference centre for STS in Poland, has reached its enrolment target of 40 patients.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP: